Suppr超能文献

单腔与双腔植入式心脏复律除颤器或无心动过缓起搏指征患者的植入式心脏复律除颤器程控:系统评价和荟萃分析。

Single vs. dual chamber implantable cardioverter-defibrillators or programming of implantable cardioverter-defibrillators in patients without a bradycardia pacing indication: systematic review and meta-analysis.

机构信息

Department of Medicine, Duke University Medical Center, Durham, NC, USA.

Duke Clinical Research Institute, Durham, NC, USA.

出版信息

Europace. 2018 Oct 1;20(10):1621-1629. doi: 10.1093/europace/euy183.

Abstract

AIMS

Implantable cardioverter-defibrillators (ICDs) are key in the prevention of sudden cardiac death, but outcomes may vary by type of device or programming [single chamber (SC) vs. dual chamber (DC)] in patients without a bradycardia pacing indication. We sought to meta-analyse patient outcomes of randomized trials of SC vs. DC devices or programming.

METHODS AND RESULTS

We searched PubMed, Embase, Scopus, Web of Science, and Cochrane trials databases for relevant studies excluding those published before 2000, involving children, or not available in English. Endpoints included mortality, inappropriate ICD therapies, and implant complications. Endpoints with at least three reporting studies were meta-analysed. We identified eight studies meeting inclusion criteria representing 2087 patients with 16.1 months mean follow-up. Mean age was 62.7 years (SD 1.92); in six studies reporting sex, most patients were male (85%). Comparing patients with a SC or DC ICD or programming, we found similar rates of mortality [odds ratio (OR) 0.95, 95% confidence interval (CI) 0.54-1.68; P = 0.86] and inappropriate therapies (OR 1.46, 95% CI 0.97-2.19; P = 0.07) in five and six studies, respectively. In three studies of SC vs. DC ICDs (but not programming) rates of pneumothorax and lead dislodgement were not different (OR 2.12, 95% CI 0.18-24.72; P = 0.55 and OR 0.87, 95% CI 0.32-2.47; P = 0.83, respectively).

CONCLUSION

In this meta-analysis of randomized controlled trials comparing SC vs. DC ICD device or programming, there was no significant difference in inappropriate therapies, mortality, pneumothorax, or lead dislodgement. Future studies should compare these devices over longer follow-up and in specific patient populations.

摘要

目的

植入式心脏复律除颤器(ICD)在预防心脏性猝死方面发挥着关键作用,但在没有心动过缓起搏指征的患者中,不同类型的设备或程控(单腔 [SC] 与双腔 [DC])可能会导致不同的结果。我们旨在对 SC 与 DC 设备或程控的随机试验患者结局进行荟萃分析。

方法和结果

我们检索了 PubMed、Embase、Scopus、Web of Science 和 Cochrane 临床试验数据库,排除了 2000 年前发表的、涉及儿童的或英文不可用的研究。研究终点包括死亡率、不恰当的 ICD 治疗和植入并发症。至少有 3 项报告研究的终点进行了荟萃分析。我们确定了 8 项符合纳入标准的研究,共纳入 2087 例患者,平均随访 16.1 个月。患者平均年龄为 62.7 岁(标准差 1.92);在 6 项报告性别情况的研究中,大多数患者为男性(85%)。比较 SC 或 DC ICD 或程控患者,我们发现死亡率[比值比(OR)0.95,95%置信区间(CI)0.54-1.68;P=0.86]和不恰当治疗率[OR 1.46,95% CI 0.97-2.19;P=0.07]在 5 项和 6 项研究中相似。在 3 项 SC 与 DC ICD 研究中(但编程研究中没有),气胸和导联脱位的发生率没有差异[OR 2.12,95% CI 0.18-24.72;P=0.55 和 OR 0.87,95% CI 0.32-2.47;P=0.83,分别]。

结论

在这项比较 SC 与 DC ICD 设备或程控的随机对照试验荟萃分析中,不恰当的治疗、死亡率、气胸或导联脱位之间无显著差异。未来的研究应在更长的随访时间和特定的患者人群中比较这些设备。

相似文献

引用本文的文献

1
[History of the implantable cardioverter-defibrillator in Germany].[德国植入式心脏复律除颤器的历史]
Herzschrittmacherther Elektrophysiol. 2024 Mar;35(Suppl 1):55-67. doi: 10.1007/s00399-024-01001-5. Epub 2024 Feb 29.
2
Implantable Cardioverter-Defibrillator for Primary Prevention in Asia.亚洲用于一级预防的植入式心脏复律除颤器
JACC Asia. 2023 Mar 7;3(3):321-334. doi: 10.1016/j.jacasi.2022.11.014. eCollection 2023 Jun.

本文引用的文献

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验